Sphingosine Kinase‐1 inhibitor, PF‐543 ameliorates Bronchopulmonary Dysplasia in a neonatal murine model

Anantha Harijith,Alison W Ha,David L Ebenezer,Panfeng Fu,Evgeny Berdyshev,Prasad Kanteti,Viswanathan Natarajan
DOI: https://doi.org/10.1096/fasebj.31.1_supplement.60.8
2017-04-01
The FASEB Journal
Abstract:Background We have earlier demonstrated that genetic knock out of sphingosine kinase1 (SphK1) ameliorated hyperoxia (75%) induced lung injury in a neonatal murine model of bronchopulmonary dysplasia (BPD). SphK 1 catalyzes the formation of sphingosine‐1‐phosphate (S1P), which acts through G protein coupled receptors S1P1–5. Exposure of neonatal mice pups to hyperoxia enhanced SphK1 expression and S1P levels and promoted formation of reactive oxygen species (ROS) in lungs. In vitro, exposure of human lung microvascular endothelial cells (HLMVECs) to hyperoxia (3–24 h) stimulated SphK1 activity, S1P generation and ROS production via p47 phox , which was blocked by PF‐543, a potent and specific SphK1 inhibitor. Hypothesis PF‐543 protects neonatal lungs from hyperoxia‐induced BPD. Methods Neonatal mice were administered PF‐543 (5 mg/kg/dose, intraperitoneal injection) starting on postnatal day 3 (PN3) and exposed to normoxia or hyperoxia (75% O 2 ) for 7 days. Mice received three additional doses of PF‐543, which were administered on alternate days and mice were sacrificed on PN 11. Broncho alveolar lavage (BAL) fluid and lung tissue were collected, and markers of inflammation and lung histology were evaluated. Plasma S1P levels were measured to determine the efficacy of PF‐543 in inhibiting SphK1. Results SphK1 inhibition by PF‐543 resulted in amelioration of hyperoxia‐induced BPD as evidenced by improved alveolarization characterized by decreased mean linear intercept compared to controls. Also, neonatal pups that received PF‐543 showed decreased infiltration of inflammatory cells in alveolar space, lower levels of protein and ROS in BAL fluid compared to controls. Administration of PF543 was accompanied by reduced plasma S1P levels. Conclusions Inhibition of SphK1 activity by, PF‐543 significantly reduced hyperoxia‐induced lung inflammation and BPD in newborn mice. These results suggest that PF‐543 can serve as a potential therapeutic drug to treat BPD. Support or Funding Information This work was supported by the University of Illinois at Chicago (UIC) Proof of Concept grant to A.H and by the National Institutes of Health Grant P01 HL98050 to V.N.
cell biology,biochemistry & molecular biology,biology
What problem does this paper attempt to address?